Hospital Antwerp, Antwerp, Belgium; 5EORTC Data Center, Brnsels, Belgimn. (Ritchie et al., 1983) . The median survival for these patients is, independent of treatment, 6-12 months (De Forges et al., 1988) . Spontaneous regression of metastases after tumour nephrectomy occurs in less than 1% (Montie, 1977) . Treatment with hormones and chemotherapy, both single agent and combination, has no proven impact on survival (Harris et al., 1983; Yagoda and Bander, 1989 (Goldstein and Laslo, 1986; Krown, 1987; Sarna et al., 1987; Muss, 1988, Buzaid and Todo, 1989; Horoszewski and Murphy, 1989 Quesada et al., 1987; Gamick et al., 1988; Otto et al., 1988; Aulitzky et al., 1989; Bruntsch et al., 1990) . Little information is available about the optimal dose, schedule and route of IFN-'y administration.
Modification of the host response is frequently restricted to a narrow dose range, and in a recent study optimal modulation by rIFN-y has been found in the low dose range (100 pg m-) (Maluish et al., 1988) The combination of IFN-a and IFN--y has ben explored on the basis of in vitro observations indicating a synergism between rIFN-y and rIFN-a (Czarnieci et al., 1984; Hubbell et al., 1987) . The results published so far are, however, disappointing (Kurzrock et al., 1986; Foon et al., 1988; Quesada et al., 1988; Ernstoff et al., 1990) . De Mulder and co-workers (Geboers et al., 1988; De Mukler et al., 1990) studied the efficacy of the combination of an escalating dose rEFN-a;z, (6pgm-2=2x 10Um2 staring dose) and a fixed low dose of rIFN-(100 g m-2 = 2 x 10' m-) twice weekly subcutaneously in patients with advanced progresive renal cell carcinoma. The overall response rate was 26% (two CRs, six PRs). The maximal tolerated dose of was 30 gm 2 (6-36 pg m-). The feasibility and efficacy of this approach was proven in the tratment of a second cohort of patients (De Mulder et al., 1991 (Figure 1 ). The time to progression is given in Figure 2 . When the patients with their primary in situ are excluded, the observed response rate was 7/42 (17%) for treatment arm A and 2/38 (5%) for arm B. The characteristics of all responding patients are shown in Table III . Six out of nine responded in the lungs, however only in two patients was this the only site of disease. In two patients concomitant metastases in the liver disappeared during therapy. The sites with unmeasurable disease remained clinically unchanged. Two patients had cytological proof of renal cell carcinoma in the enlarged node prior to the start of treatment. After discontinuation of treatment lymph node dissection was performed. Pathological examination revealed no tumour and the patients are therefore considered as having a pathological CR. One possible explanation for the lack of response in the combination arm could be a difference in the dose intensity of rIFN-w. in the two groups. However, dose intensity, dose reductions and delays were similar in the two arms. In both arms 90% of the patients received 100% of the intended dose of rIFN-2. 
Toxicity
Observed grade II and III toxicity is given in Table IV obtained from pooled data is about 17% (Krown, 1987; Muss, 1988; Horoszewicz et al., 1989; De Mulder et al., 1991) . (Geboers et al., 1988) .
In the present multicentre study the activity of IFN-a is confirmed with an overall response rate of 13%. When only patients without their primary tumour are analysed, the response rate is 17%, which is consistent with the range observed in the literature. One should realise that these results were obtained with a relatively low dose of IFN-a (10 x 106 IU m-) and a twice-weekly schedule, again an indication that the regimen is not critical and that IFN-x given above a certain threshold is able to induce responses in sensitive tumours. A remarkable finding was that in two patients an objective response in the liver was seen.
The main purpose of the study was to study the relevance of the addition of IFN-y, which was based both on laboratory observations as well as on the results of earlier studies. The results were very disappointing because only in two patients (4%) was an objective response observed and the study, initially planned as a randomised phase III study, was stopped after an interim analysis. As indicated before, the probability of obtaining these results if a difference of 10% in favour of the combination was actually present is extremely low. Equivalence in outcome or even the inverse outcome, i.e. a potential adverse effect of the combination, cannot be excluded with adequate power in view of the numbers involved, but this was not the purpose of the study. There is no satisfactory explanation for this result. Patient characteristics of the two patient populations were similar and the likelihood that this observation could have been made by chance is almost negligible. The mechanisms of action of IFN-x are very pleiotropic, and many mechanisms can be responsible for the observed anti-tumour effect. There are actions directly on the tumour such as an antiproliferative effect, and there are indications that the induction of 2',5'-oligoadenylate synthetase is related with this potential (Grander et al., 1990) . On the other hand, immunological properties such as the induction of natural killer activity and the enhancement of the expression of antigens on the tumour might play a role. The mechanism of action as elucidated in hairy cell leukaemia (Vedantham et al., 1992) , the carcinoid (Grander et al., 1990) and the observation that the addition of 20 mg of prednisone had no impact on the anti-tumour effect (Fossa et al., 1990) Aulitzky et al. (1989) , so far unconfirmed. applying an individually tailored dose of IFN-y based on parameters of immune stimulation such as neopterin excretion. indicates the sensitivity of this disease depending on very specific requirements. The IFN-y dose used in the present study was within the same range. One of the explanations of the generally low response rate in combination studies could be the relatively low dose of IFN-given in these studies (De Mulder et al., 1991) . In the present study this explanation is unlikely in view of the almost identical dose intensity of IFN-2c in the two treatment arms.
Based on these results, the combination of IFN-a and IFN-y in the dose and schedule described in this study cannot be recommended. Our results confirm the limited activity of IFN-a monotherapy in this disease.
